# Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis

> **NCT00682656** · PHASE2,PHASE3 · TERMINATED · sponsor: **Ana Rabello** · enrollment: 48 (actual)

## Conditions studied

- Cutaneous Leishmaniasis

## Interventions

- **DRUG:** Glucantime®
- **DRUG:** Zithromax ®

## Key facts

- **NCT ID:** NCT00682656
- **Lead sponsor:** Ana Rabello
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2011-12
- **Final completion:** 2012-09
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Efficacy issues on test arm
- **Last updated:** 2014-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682656, "Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00682656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*